Apellis Pharmaceuticals Acquired by Biogen | Healthcare M&A Deal

Biogen has completed the acquisition of Apellis Pharmaceuticals, a ophthalmology business in Massachusetts. Apellis Pharmaceuticals develops therapies for eye diseases, supporting treatment innovation in retinal and other ophthalmic conditions. Biogen acquires Apellis Pharmaceuticals to expand its healthcare portfolio and strengthen its ophthalmology acquisition strategy. The merger acquisition is classified as strategic acquisition within healthcare M&A, with deal size undisclosed and status closed.